Black Diamond Therapeutics, Inc. (BDTX): Submission of Matters to a Vote of Security Holders
Black Diamond Therapeutics, Inc. (BDTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001701541 0001701541 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
How this was made
The 30-second read
Why it matters
Item 5.07 confirms stockholder approval of director nominees, ratification of PricewaterhouseCoopers for 2026, and non-binding say-on-pay and say-on-frequency (annual).
Market read
This is a routine governance/proxy-results disclosure with no new financial or clinical catalyst described.
What to watch
Check the related April 29, 2026 proxy statement for any contested items or director background changes; this 8-K itself only provides final tallies.
Background
The filing reports final results from Black Diamond Therapeutics’ 2026 virtual annual meeting held June 26, 2026.
Ticker impact
Black Diamond Therapeutics reported final 2026 annual meeting voting results, including election of two Class III directors and ratification of PwC.
Low likelihood of a sustained price move; any reaction should be muted and short-lived.
The 8-K is a standard Item 5.07 disclosure of proxy vote tallies (board election, auditor ratification, say-on-pay), without new guidance, financing, litigation, or clinical/product updates.
Market effects
No sector-level read-across; governance vote outcomes are company-specific and not indicative of biotech pipeline changes.
Minimal; Nasdaq-listed governance filing typically does not drive broader regional risk sentiment.
Low; no cross-border transaction or regulatory action disclosed.
Counterpoint
If investors were concerned about board composition or auditor continuity, the final vote counts could reduce uncertainty, but the filing still lacks new fundamentals.
Key entities
- issuerBlack Diamond Therapeutics, Inc.
Nasdaq-listed company filing the 8-K; reported final stockholder voting results for board, auditor, and advisory compensation matters.
- auditorPricewaterhouseCoopers LLP
Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.
- director nomineeShannon Campbell
Elected as Class III director at the annual meeting.
- director nomineeKapil Dhingra
Elected as Class III director at the annual meeting.
